Published in Vaccine Weekly, March 22nd, 2006
"We studied serum monocyte chemotactic protein-1 (MCP-1) levels in breast cancer patients in relationship to their clinicopathologic variables and immune response to a HER-2/neu E75 vaccine," researchers in the United States report.
Zia A. Dehqanzada and colleagues at the Uniformed Services University of the Health Sciences explained, "We measured MCP-1 levels in 32 HER-2/neu+ breast cancer patients before and after vaccination with a HER-2/neu E75 peptide + granulocyte macrophage colony-stimulating factor vaccine. Clinical...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly